Treatment of Behcet's Disease: An Algorithmic Multidisciplinary Approach

被引:45
作者
Alpsoy, Erkan [1 ]
Leccese, Pietro [2 ,3 ]
Emmi, Giacomo [4 ]
Ohno, Shigeaki [5 ,6 ]
机构
[1] Akdeniz Univ, Sch Med, Dept Dermatol & Venereol, Antalya, Turkey
[2] San Carlo Hosp Potenza, Rheumatol Dept Lucania, Rheumatol Inst Lucania, Potenza, Italy
[3] Madonna Grazie Hosp Matera, Matera, Italy
[4] Univ Firenze, Dept Expt & Clin Med, Florence, Italy
[5] Aishin Mem Hosp, Ophthalmol Ctr, Sapporo, Hokkaido, Japan
[6] Hokkaido Univ, Dept Ophthalmol, Fac Med, Grad Sch Med, Sapporo, Hokkaido, Japan
关键词
algorithms; therapeutics; morbidity; mortality; Behç et' s disease; ANTI-TNF-ALPHA; PULMONARY-ARTERY INVOLVEMENT; DAGGER-ETS DISEASE; DOUBLE-BLIND TRIAL; CYCLOSPORINE-A; INTESTINAL INVOLVEMENT; MUCOCUTANEOUS LESIONS; CLINICAL-FEATURES; APHTHOUS ULCERS; OCULAR LESIONS;
D O I
10.3389/fmed.2021.624795
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Behcet's disease (BD) is a chronic, relapsing inflammatory, multisystem disease of unknown etiology. The disease has a wide clinical spectrum of mucocutaneous lesions and ocular, vascular, articular, neurologic, gastrointestinal and cardiac involvement. Although the number of effective drugs used in the disease's treatment has increased in recent years, BD is still associated with severe morbidity because of mainly mucocutaneous, articular and ocular symptoms and an increased mortality because of large vessel, neurological, gastrointestinal and cardiac involvement. Many factors are associated with a more serious course, such as male gender and a younger age of onset. While the severity of the disease is more pronounced in the first years of the disease, it decreases in most patients after the age of forties. The primary goal of treatment should be the prevention of irreversible organ damage. Therefore, early diagnosis and appropriate treatment and close follow-up are mandatory to reduce the morbidity and mortality of the disease. Treatment varies depending on the organ involved and the severity of the involvement. For all these reasons, the treatment should be personalized and arranged with a multidisciplinary approach according to the organs involved. Treatment is mainly based on suppression of the inflammatory attacks of the disease using local and systemic immunomodulatory and immunosuppressive drugs. In this review, based on the mainly controlled studies and personal experience in clinical practice and basic research in this field, we propose a stepwise, symptom-based, algorithmic approach for the management of BD with a holistic perspective.
引用
收藏
页数:11
相关论文
共 109 条
  • [81] Interferon-α treatment for acute myelitis and intestinal involvement in severe Behcet's disease
    Monastirli, A.
    Chroni, E.
    Georgiou, S.
    Ellul, J.
    Pasmatzi, E.
    Papathanasopoulos, P.
    Tsambaos, D.
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2010, 103 (10) : 787 - 790
  • [82] MORAL F, 1995, CLIN EXP RHEUMATOL, V13, P493
  • [83] A Major Review: Current Aspects of Ocular Belket's Disease in Japan
    Namba, Kenichi
    Goto, Hiroshi
    Kaburaki, Toshikatsu
    Kitaichi, Nobuyoshi
    Mizuki, Nobuhisa
    Asukata, Yuri
    Fujino, Yujiro
    Meguro, Akira
    Sakamoto, Shunya
    Shibuya, Etsuko
    Yokoi, Katsutoshi
    Ohno, Shigeaki
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2015, 23 : S1 - S23
  • [84] Interferon-alpha 2a treatment of neuro-Behcet disease
    Nichols, JC
    Ince, A
    Akduman, L
    Mann, ES
    [J]. JOURNAL OF NEURO-OPHTHALMOLOGY, 2001, 21 (02) : 109 - 111
  • [85] Long-Term Outcome of Neuro-Behcet's Disease
    Noel, Nicolas
    Bernard, Remy
    Wechsler, Bertrand
    Resche-Rigon, Matthieu
    Depaz, Raphael
    Boutin, Du Le Thi Huong
    Piette, Jean-Charles
    Drier, Aurelie
    Dormont, Didier
    Cacoub, Patrice
    Saadoun, David
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 (05) : 1306 - 1314
  • [86] Ohno S, 2016, INTRAOCULAR INFLAMMA, P785
  • [87] Management of major organ involvement of Behcet's syndrome: a systematic review for update of the EULAR recommendations
    Ozguler, Yesim
    Leccese, Pietro
    Christensen, Robin
    Esatoglu, Sinem Nihal
    Bang, Dongsik
    Bodaghi, Bahram
    Celik, Aykut Ferhat
    Fortune, Farida
    Gaudric, Julien
    Gul, Ahmet
    Koetter, Ina
    Mahr, Alfred
    Moots, Robert J.
    Richter, Jutta
    Saadoun, David
    Salvarani, Carlo
    Scuderi, Francesco
    Sfikakis, Petros P.
    Siva, Aksel
    Stanford, Miles
    Tugal-Tutkun, Ilknur
    West, Richard
    Yurdakul, Sebahattin
    Olivieri, Ignazio
    Yazici, Hasan
    Hatemi, Gulen
    [J]. RHEUMATOLOGY, 2018, 57 (12) : 2200 - 2212
  • [88] LOW-DOSE CYCLOSPORINE-A VERSUS PULSED CYCLOPHOSPHAMIDE IN BEHCETS-SYNDROME - A SINGLE MASKED TRIAL
    OZYAZGAN, Y
    YURDAKUL, S
    YAZICI, H
    TUZUN, B
    ISCIMEN, A
    TUZUN, Y
    AKTUNC, T
    PAZARLI, H
    HAMURYUDAN, V
    MUFTUOGLU, A
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 1992, 76 (04) : 241 - 243
  • [89] Updated treatment strategies for intestinal Behcet's disease
    Park, Yong Eun
    Cheon, Jae Hee
    [J]. KOREAN JOURNAL OF INTERNAL MEDICINE, 2018, 33 (01) : 1 - 19
  • [90] Hemoptysis in Behcet's syndrome: from bedside to bench?
    Rossi, Giovanni Maria
    Emmi, Giacomo
    Vaglio, Augusto
    [J]. INTERNAL AND EMERGENCY MEDICINE, 2018, 13 (04) : 467 - 469